Navigation Links
Biomedical Research Centre searches for immunological biomarkers
Date:10/15/2009

Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection. But the molecular and cellular processes triggering these inflammatory and immune responses remain little understood. A group of London-based researchers hope that by extending understanding of the biological processes, they will be able to identify 'biomarkers' in the tissue and blood, which in future could be used to diagnose these conditions, to predict how they will develop and how an individual will respond to treatment.

The 500,000 research programme is being carried out at National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London, working in partnership with King's College Hospital NHS Foundation Trust and Barts and The London School of Medicine and Dentistry

Professor Frank Nestle, Mary Dunhill Chair of Cutaneous Medicine and Immunotherapy at King's College London, explains: "We want to test the theory that there are common immunological pathways underlying many chronic inflammatory diseases and that these could serve as valuable biomarkers for diagnostic, prognostic and therapeutic purposes."

Key to the success of this research programme is the Biomedical Research Centre's immune monitoring core, which consists of cutting-edge high throughput flow cytometric analysis and flow sorting equipment as well as multiplex cytokine analysis equipment. This technology enables researchers to analyse events within particular cell types involved in the body's immune response, such as T cells and dendritic cells, in minute detail with statistical accuracy.

In addition, the Centre's strategic agreement with BD Biosciences, a segment of BD, a leading global medical technology company, enables its investigators to access BD Biosciences' novel flow based technologies, reagents in the development pipeline and to co-develop and commercialise potential immunological biomarkers.

Researchers will use these technologies to study the activities within the cells of healthy volunteers to establish a range of variance in the normal population and develop a potential immunological signature (a combination of immune markers characteristic for a given cell type or its state of activation).

They will then test this signature using tissue and blood samples taken from patients with psoriasis, kidney transplant rejection and rheumatoid arthritis in the first instance to see if it can be accurately used for the early diagnosis of these conditions. Following this, they will undertake a series of prospective studies to test the predictive accuracy of the signatures in relation to disease progression and response to therapies, before studying other conditions, such as ulcerative colitis, Crohn's disease and transplant rejection.

Professor Graham Lord, Deputy Director of the Biomedical Research Centre said: "This research programme is hugely exciting as it brings our patients together with cutting-edge technology, basic science and clinical medicine. By carrying out detailed studies of cell activity, we aim to develop an immunological biomarker set that will transform the way that a number of specific inflammatory conditions are diagnosed and managed in future. Our patients will be the first to benefit from any new discoveries."


'/>"/>

Contact: Andrea Ttofa
andrea.ttofa@gstt.nhs.uk
44-020-718-85577
King's College London
Source:Eurekalert

Related medicine news :

1. Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations
2. Sponsor-A-Scientist: New Option to Fund Biomedical Research
3. Biomedical Research Centre developing enhanced cells as therapies
4. Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA-MED(R) Monoplace Hyperbaric Chamber Sale in Romania
5. New test for safer biomedical research results
6. Successful Beginning for Wellstone Muscular Dystrophy Center at Boston Biomedical Research Institute
7. 17 of Americas Most Promising Scientists Selected as 2009 Pew Scholars in the Biomedical Sciences
8. Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer
9. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
10. New Video Series Spotlights Role of Biomedical Engineers in Caring for Total Artificial Heart Patients
11. Response Biomedical Closes $12.65 million Unit Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... PA and LONDON, UK (PRWEB) , ... May 06, 2016 , ... ... accolades for his success in changing the way the pharmaceutical industry conducts clinical trials. ... of the world’s most influential people in pharma, and he was honored as a ...
(Date:5/6/2016)... ... May 06, 2016 , ... Bluvault ( Bluvault Inc. ) ... for global clients of Coupa ( Coupa Software ) and other Cloud software, ... a key component in the suite of innovative implementation services offered by Bluvault. ...
(Date:5/6/2016)... ... May 06, 2016 , ... From May 4 to 6, ... members the unique opportunity to learn more about Signia’s technology and the successful business ... “It is our priority to see practices succeed in this highly competitive industry,” said ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning plumbing ... for over 35 years. Maintaining core values of exceptional customer service, quality work at ... them a leading name in San Diego plumbing, and other services including heating & ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... David Konur, CEO of Cardiovascular Institute of the South announced today that Dr. ... a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. , ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... May 5, 2016 ... addition of the  "Europe Thrombocytopenia Market ...  report to their offering.  ... , ,The latest research Europe Thrombocytopenia ... 2016, provides comprehensive insights into Thrombocytopenia ...
(Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
(Date:5/4/2016)... Israel , May 4, 2016 ... that BiondVax,s CEO, Dr. Ron Babecoff , will be ... New York City . On Thursday, May ... 2016, a conference presented by Joseph Gunner & ... The BiondVax presentation that Dr. Babecoff will be using ...
Breaking Medicine Technology: